Figure 1From: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatmentMean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) at baseline and after 1 and 2 years in a tumor necrosis factor-alpha blocker-naĂ¯ve cohort of ankylosing spondylitis patients. ns, not significant.Back to article page